<DOC>
	<DOCNO>NCT02303509</DOCNO>
	<brief_summary>To evaluate safety tolerability UCB5857 . Part 1 study explores single dos drug . Part 2 study explores give drug every day 14 day . The study use healthy psoriasis subject .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetic &amp; Pharmacodynamic Effect UCB5857 Healthy &amp; Psoriatic Subject</brief_title>
	<detailed_description>This first-in-human ( FIH ) , Phase 1 , randomize , double-blind , placebo control , single center study design evaluate safety/ tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) UCB5857 follow oral administration single ascend dos ( SAD ) healthy subject ( Part 1 ) multiple ascend dos ( MAD ) healthy mild-to-moderate psoriatic subject ( Part 2 ) . The primary objective study investigate safety tolerability UCB5857 give single oral dos healthy subject ascend multiple oral dos healthy subject mild-to-moderate psoriatic subject .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject male female , age 18 55 year ( inclusive ) . Female subject must negative serum pregnancy test Screening , nonchildbearing potential , define : Being postmenopausal ( least 2 year prior Screening ) , verify serum folliclestimulating hormone ( FSH ) level &gt; 40 mIU/ mL Screening , Having undergone complete hysterectomy , bilateral tubal ligation , and/ bilateral oophorectomy , Being congenital sterile Male subject confirms , study period period 3 month 5 half life last administration IMP ( whichever longer ) , sexual intercourse woman childbearing potential , method highly effective contraception use ( eg , condom + spermicide , additional contraceptive method use partner ) . Male contraception require male subject undergone effective vasectomy &gt; 3 month prior study ; however , female partner must use contraceptive method study period period 3 month 5 halflives last administration IMP ( whichever longer ) Subject normal weight determine body mass index ( BMI ) 18.0 30.0 kg/ m2 ( inclusive ) , body weight least 50 kg ( healthy subject ) Subject good physical mental health , opinion Investigator , determine basis medical history general clinical examination Screening Subject clinical laboratory test result within reference range test laboratory . Subjects isolated test result outside specified range deem clinically nonsignificant allow discretion Investigator , follow discussion Sponsor 's Study Physician , exclude ALT , AST , alkaline phosphate bilirubin , within normal range . If subject 1 isolated test result outside specific range deem clinically significant , rescreening may allow discretion Investigator , follow discussion Sponsor 's Study Physician Subject BP pulse rate within normal range supine position 5 minute rest ( systolic BP : 90 140 mmHg , diastolic BP : 50 90 mmHg , pulse rate : 40 90 bpm ) . Results outside specify range deem clinically nonsignificant allow discretion Investigator , follow discussion Sponsor 's Study Physician . If subject 1 isolated finding outside specific range deem clinically significant , rescreening may allow discretion Investigator , follow discussion Sponsor 's Study Physician Subject body temperature ( oral tympanic ) 35.0 37.5°C ( 95 99.5°F ) inclusive Subject 's ECG consider `` normal '' `` abnormal '' clinically nonsignificant ( interpreted Investigator ) . If subject 1 isolated finding outside specific range deem potentially clinically significant , rescreening may allow discretion Investigator , follow discussion Sponsor 's Study Physician In addition psoriatic subject cohort Subject BMI Screening &lt; 35 kg/ m2 Subject confirm diagnosis mildtomoderate plaquetype psoriasis least 6 month involve ≤10 % BSA ( exclude scalp ) Subject minimum 2 psoriatic lesion least 1 plaque site suitable biopsy Subjects permit enroll study follow criterion meet : Healthy psoriatic subject Subject employee direct relative employee PAREXEL Sponsor Subject participate another study investigational medication ( medical device ) within last 3 month 5 halflives study medication , whichever longer , currently participate another study investigational medication ( medical device ) Subject make blood donation ( &gt; 400mL ) comparable blood loss ( &gt; 350 mL ) within 3 month prior first intake study drug Subject test positive human immunodeficiency virus1/2 antibody ( HIV1/2Ab ) , hepatitis B surface antigen , hepatitis C virus antibody . Subject willing avoid heavy physical exertion 2 day drug administration study Subject history alcohol and/or drug abuse 6 month Screening Subject alcohol consumption 21 unit ( male ) 14 unit ( female ) alcohol per week ( 1 unit alcohol equivalent 10 mL ethanol ; example , 330 mL 5 % alcohol volume beer =1.7 unit ; 125 mL 12 % wine =1.5 unit : 50 mL spirit 40 % alcohol volume =2 unit ) Subject test positive alcohol and/or drug ( urine test ) Screening Day 1 Subject receive prescription ( include hormonal replacement therapy ) nonprescription medicine , include overthecounter ( OTC ) remedy , herbal , dietary supplement ( vitamin within recommended daily dose limit ) , within 21 day 5 halflives respective drug , whichever longer , prior Checkin ( Day 1 ) , occasional use analgesic paracetamol ( acetaminophen ) , ibuprofen , intranasal corticosteroid seasonal rhinitis Subject consume grapefruit , grapefruit juice , grapefruitcontaining product , well St John 's Wortcontaining product , within 14 day prior Checkin ( Day 1 ) Subject know hypersensitivity component IMP Subject current past history GI ulceration Subject consider antiimmunoglobulin E ( IgE ) nonresponsive CD63 induction basophil &lt; 10 % . Subject cardiovascular cerebrovascular disease , include hypertension , angina , ischemic heart disease , transient ischemic attack , stroke , peripheral arterial disease sufficient cause symptom and/ require therapy maintain stable status Subject diabetes mellitus type require insulin Subject unstable/poorly control Type 2 diabetes mellitus , define glycosylated hemoglobin type A1c ( HbA1c ) level ≥8.5 % glucose intolerant Subject Has active infection ( eg , sepsis , pneumonia , abscess ) Has history latent , chronic , recurrent infection ( eg , tuberculosis , recurrent sinusitis , genital herpes , urinary tract infection ) risk infection ( surgery , trauma , infection require antibiotic , history skin abscess ) within 3 month prior IMP administration Has experience significant episode gastroenteritis ( define loose stool associate abdominal pain and/ fever ) 7 day prior IMP administration When doubt , Investigator confer Sponsor 's Study Physician Subject history positive tuberculosis ( TB ) test evidence possible TB latent TB infection Screening ( interferon gamma release assay [ IGRA ] test ) Subject receive live attenuate vaccination within 3 month type vaccine within 4 week prior Screening intend vaccination course study Subject follow hematology value Screening : Hemoglobin ; woman &lt; 11 g/ dL ; men &lt; 13 g/ dL ANC &lt; 1.5x109/ L ( &lt; 1500/ μL ) Subject abnormality 12lead ECG , opinion Investigator , increase risk associate participate study . In addition subject follow finding exclude : QTcF interval &gt; 450 m 2 3 ECGs . Bundle branch block conduction abnormality ( mild first degree atrioventricular block ) PR interval ≥220 m Irregular rhythm sinus arrhythmia occasional , rare supraventricular rare ventricular ectopic beat In judgment Investigator , Twave configuration sufficient quality assess QT interval duration Subject active neoplastic disease history neoplastic disease within 5 year Screening ( except basal squamous cell carcinoma skin carcinoma situ definitively treat standard care ) Subject acute chronic illness , opinion Investigator Sponsor 's Study Physician , could pose threat harm subject Subject legally institutionalize mental health condition relate care provision ( eg , guardianship ) would impede subject provide voluntary informed consent participate study Healthy subject The subject use nicotinecontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 6 week prior Checkin ( Day 1 ) anticipate inability abstain product duration study Subject high consumption xanthinecontaining product ( ≥300 mg xanthine equivalent per day [ 1 cup coffee ≈ 100 mg caffeine ; 1 cup tea ≈ 30 mg caffeine ; 1 glass cola ≈ 20 mg caffeine ] ) Psoriatic subject Subject receive systemic nonbiologic psoriasis therapy ( methotrexate [ MTX ] , steroid , cyclophosphamide ) psoralen plus ultraviolet A ( PUVA ) /ultraviolet A ( UVA ) phototherapy within 4 week prior Screening . Subject receive treatment biologic agent within 12 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Mild moderate Psoriasis</keyword>
	<keyword>Subjects</keyword>
</DOC>